Awakn Life Sciences Corp. (OTC: AWKNF), a biotech firm focused on developing therapies for addiction, with a primary emphasis on Alcohol Use Disorder (AUD), has taken a big step toward Phase III clinical trial initiation today. The company has submitted a Clinical Trial Application (CTA) for a phase III clinical trial involving their leading program, AWKN-P001, designed for the treatment of Severe Alcohol Use Disorder (SAUD).
Awakn's planned Phase III trial of AWKN-P001 will be an n=280, two-armed randomized placebo-controlled trial, delivered in the UK across ten @NHSuk sites. For more information, visit: https://t.co/WoxcgctXOm $AWKN $AWKNF
— Awakn™ Life Sciences (@awakn_ls) September 6, 2023
AWKN-P00, a novel combined therapeutic consisting of racemic ketamine and delivered via intravenous (IV), represents an innovative treatment approach …